STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIRB) announced today that their research development and license agreement, in the field of HIV-protease inhibitors, with Tibotec Pharmaceuticals Ltd. is extended for a further year and includes research funding. The programme is presently in preclinical research.
